Retinoid therapy of childhood cancer

Hematology/Oncology Clinics of North America

Volumn 15, Issue 5, 2001, Pages 867-910

  Reynolds, C Patrick ^a   Lemons, Richard S ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTARABINE; DAUNORUBICIN; FENRETINIDE; HISTONE ACETYLTRANSFERASE; ISOTRETINOIN; RETINAL; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; BINDING AFFINITY; BINDING KINETICS; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL MATURATION; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; NEPHROTOXICITY; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

EID: 0035675374     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70256-2     Document Type: Article

References (283)

1. Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis-retinoic acid in a patient with myelodysplastic syndrome: Inhibition of growth of the patient's malignant monocytoid clone
2. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer
3. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule
4. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer
5. All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells
6. Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells
7. Modulation of cell surface antigens of a murine neuroblastoma
8. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus
9. Maturation of neuroblastoma to ganglioneuroma
10. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: Comparison with intensive chemotherapy
11. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
12. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia
13. Modulation by retinoic acid of insulin-like growth factor (IGF) and IGF binding protein expression in human SK-N-SH neuroblastoma cells
14. A phase I pharmacokinetic study of fenretinide (HPR) in children with high-risk solid tumors
15. Phase I study of 13-cis-retinoic acid toxicity
16. Expression of a drug resistance gene in human neuroblastomacell lines: Modulation by retinoic acid-induced differentiation
17. Fenretinide cytotoxicity in Ewing's sarcoma (ES) and primitive neuroectodermal (PNET) cell lines is blunted by hypoxia but synergistically enhanced by safingol
18. Differential retinoic acid radiosensitization of cervical carcinoma cell lines
19. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase
20. Isomerization of all-trans-retinoids to 11-cisretinoids in vitro
21. Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia
22. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction
23. Acute promyelocytic leukemia in children: Experience of the Italian Pediatric Hematology and Oncology Group (AIEOP)
24. Transport and metabolism of vitamin A
25. Molecular analysis of the t(15;17) translocation in acute promyelocytic leukaemia
26. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression
27. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid
28. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60
29. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid
30. A retinoic acid resistant HL-60 cell clone sensitive to N-(4-hydroxyphenyl) retinamide-mediated clonal growth inhibition
31. Histochemical demonstration of an increase in acetylcholinesterase in established lines of human and mouse neuroblastomas by nerve growth factor
32. Differentiating agents in pediatric malignancies: All-transretinoic acid and arsenic in acute promyelocytic leukemia
33. Recombinant gamma-interferon induces in vitro monocytic differentiation of blast cells from patients with acute nonlymphocytic leukemia and myelodysplastic syndromes
34. Phase II trial of 13-cis-retinoic acid in metastatic breast cancer
35. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results
36. A decade of molecular biology of retinoic acid receptors
37. N-(4-hydroxyphenyl)retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells
38. A transcriptional co-repressor that interacts with nuclear hormone receptors
39. SMRT isoforms mediate repression and antirepression of nuclear receptor heterodimers
40. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
41. Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation
42. All-trans retinoic acid in acute promyelocytic leukemias: II. In vitro studies - Structure-function relationship
43. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells
44. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer
45. Acute promyelocytic leukemia: Relieving repression induces remission
46. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha)
47. Tolerability of the synthetic retinoid fenretinide (HPR)
48. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
49. Retinoic acid-induced expression of tissue transglutaminase in human promyelocytic leukemia (HL-60) cells
50. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia
51. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface
52. Different combinations of retinoids and vitamin D3 analogs efficiently promote growth inhibition and differentiation of myelomonocytic leukemia cell lines
53. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid
54. 13-cis-retinoic acid with alpha-2a-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro
55. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2
56. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid
57. Role of antioxidants and intracellular free radicals in retinamide-induced cell death
58. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia
59. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus
60. Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity
61. Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells
62. The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia
63. Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide
64. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid
65. Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro
66. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
67. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
68. Anti-tumor effects of ailing-1 on human megakaryoblastic leukemia cells
69. Modulation of IL-8, IL-1 beta, and GCSF secretion by all-trans retinoic acid in acute promyelocytic leukemia
70. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine
71. Spontaneous regression of cancer
72. Spontaneous disappearance of neuroblastoma with maturation to ganglioneuroma
73. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
74. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
75. Long-term follow-up confirms the benefit of alltrans retinoic acid in acute promyelocytic leukemia
76. Acute promyelocytic leukemia: Biology and treatment
77. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia
78. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial
79. Activation of the human MDR1 gene promoter in differentiated neuroblasts
80. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the Children's Cancer Study Group
81. Cloning and chromosome mapping of human retinoid X receptor beta: Selective amino acid sequence conservation of a nuclear hormone receptor in mammals
82. Plasma retinol level reduction by the synthetic retinoid fenretinide: A one year follow-up study of breast cancer patients
83. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations
84. All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular araCTP accumulation
85. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines
86. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies
87. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: Effects on the degradation of RARalpha and PML-RARalpha
88. AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells
89. Phase II trial of 13-cis-retinoic acid in patients with advanced nonseminomatous germ cell tumors
90. Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes
91. Vitamin A metabolism
92. Vitamin A and retinoids in health and disease
93. Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer
94. Retinoids in the treatment of acute promyelocytic leukemia: Review of the literature
95. Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells
96. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): Results of the European Working Party Group
97. Phase II study of isotretinoin in the treatment of advanced non-small cell lung cancer
98. Immunophenotype of adult and childhood acute promyelocytic leukaemia: Correlation with morphology, type of PML gene breakpoint and clinical outcome: A cooperative Italian study on 196 cases
99. Regulation of Bd-2 oncoprotein levels with differentiation of human neuroblastoma cells
100. Retinoids and their nuclear receptors
101. Specific high affinity binding and biologic action of retinoic acid in human neuroblastoma cell lines
102. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor
103. Radiation sensitivity of human squamous cell carcinoma cells in vitro is modulated by all-trans and 13-cis-retinoic acid in combination with interferon-alpha
104. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
105. Recent advances in chemoprevention of cancer
106. The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells
107. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia: Report of 6 cases
108. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
109. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts
110. Neuroblastoma: Review of the literature and an examination of factors contributing to its enigmatic character
111. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3
112. Hemolytic uremic syndrome following bone marrow transplantation
113. Abnormal retinal function associated with fenretinide, a synthetic retinoid
114. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines
115. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
116. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines
117. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C
118. Gamma interferon augments functional and phenotypic characteristics of vitamin D3-induced monocytoid differentiation in the U937 human leukaemic cell line
119. Pharmacology of 13-cis-retinoic acid in humans
120. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines
121. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy
122. Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines
123. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma
124. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)
125. Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor
126. Mechanisms of resistance to apoptosis in human AML blasts: The role of differentiation-induced perturbations of cell-cycle checkpoints
127. Pharmacokinetic studies of 13-cisretinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation
128. Bcl-2 expression in neuroblastoma is differentially regulated by differentiation inducers
129. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: Clinical and basic studies for the next generation
130. Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implications
131. Expression of nerve growth factor receptor mRNAs and clinical response to retinoic acid in neuroblastoma
132. A randomized trial of 13-cis retinoic acid in children with advanced neuroblastoma after high-dose therapy
133. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines
134. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin
135. Neuroblastoma
136. Modulation of intracellular cyclic adenosine monophosphate levels and the differentiation response of human neuroblastoma cells
137. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia
138. Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance
139. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells
140. Neurite extension and malignancy of neuroblastoma cells after treatment with prostaglandin E1 and papaverine
141. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase
142. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells
143. Improved inhibitors of glucosylceramide synthase
144. Acute promyelocytic leukemia
145. Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element
146. Expression of retinoic acid receptors alpha, beta, and gamma in human neuroblastoma cell lines
147. Cancer surveillance series: Recent trends in childhood cancer incidence and mortality in the United States
148. Retinoic acid receptors: Transcription factors modulating gene regulation, development, and differentiation
149. 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix
150. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin
151. Extramedullary involvement in patients with acute promyelocytic leukemia: A report of seven cases
152. Diagnosis, front line treatment and molecular monitoring of acute promyelocytic leukaemia
153. Therapy of molecular relapse in acute promyelocytic leukemia
154. Acute promyelocytic leukemia: A curable disease
155. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs
156. Tretinoin toxicity in children with acute promyelocytic leukaemia
157. Molecular remission in PML/RAR alphapositive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
158. Retinoid receptors
159. Molecular biology of neuroblastoma
160. N-(4-hydroxyphenyl)retinamide: A potent inducer of apoptosis in human neuroblastoma cells
161. Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
162. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
163. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism
164. N-(4-hydroxyphenyl)retinamide increases ceramide and reactive oxygen species and induces mixed apoptosis/necrosis in neuroblastoma cell lines
165. Maturing neuroblastoma and ganglioneuroblastoma: A study of four cases with long survival
166. Modulation of IGF-2 expression during growth and differentiation of human neuroblastoma cells: Retinoic acid may induce IGF-2
167. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene
168. 13-cis-retinoic acid: Pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer
169. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia
170. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma
171. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases
172. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia
173. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia
174. Clinical pharmacology of all-trans retinoic acid
175. Effect of 1,25 dihydroxyvitamin D3 and retinoic acid on normal human pluripotent (CFU-mix), erythroid (BFU-E), and myeloid (CFUC) progenitor cell growth and differentiation patterns
176. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein
177. Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukaemia
178. Arsenicals in hematologic cancers
179. N-(4-hydroxyphenyl)retinamide increase ceramide and are cytotoxic for human acute lymphoblastic leukemia (ALL) cell lines
180. Adverse effects of large doses of vitamin A and retinoids
181. Vitamin A and cancer
182. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro
183. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells
184. Hemolytic uremic syndrome after bone marrow transplantation without total body irradiation
185. Modulation of normal myelopoiesis in vitro by retinoic acid
186. Phenotypic changes of human neuroblastoma cells in culture induced by 12-O-tetradecanoyl-phorbol-13-acetate
187. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: A comparison with phorbolester-induced differentiation
188. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide
189. Pharmacokinetics of N-4-hydroxyphenylretinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients
190. Cytotoxic effects of vitamin A in combination with vincristine, daunorubicin and 6-thioguanine upon cells from lymphoblastic leukemic patients
191. In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts
192. Truncation does not abrogate transcriptional downregulation of the c-myc gene by sodium butyrate in Burkitt's lymphoma cells
193. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation
194. Role of cyclic AMP in differentiation of human neuroblastoma cells in culture
195. Human neuroblastoma cell culture: Effect of 5-bromodeoxyuridine on morphological differentiation and levels of neural enzymes
196. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug
197. Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase
198. Induction of tumor cell differentiation as a therapeutic approach: Preclinical models for hematopoietic and solid neoplasms
199. Differentiating agents in pediatric malignancies: Retinoids in neuroblastoma
200. Characterization of human neuroblastoma cell lines established before and after therapy
201. Response of neuroblastoma cell lines to retinoic acid and 13-cis-retinoic acid, but not fenretinide, is mediated by retinoic acid receptors
202. Response of neuroblastoma to retinoic acid in vitro and in vivo
203. Retinoid therapy of neuroblastoma
204. Modulation of cell surface antigens accompanies morphological differentiation of human neuroblastoma cell lines
205. N-(4-hydroxyphenyl)retinamide is highly active against retinoic acid resistant neuroblastoma cell lines
206. Induction of neurite outgrowth in the IMR-32 human neuroblastoma cell line by nerve growth factor
207. Nerve growth factor induces neurite outgrowth in a clone derived from an NGF-insensitive human neuroblastoma cell line
208. Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines
209. Neuroblastoma
210. Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma
211. 13-cis-retinoic acid antagonizes cytotoxic chemotherapy in neuroblastoma cell lines
212. Biological classification of cell lines derived from human extra-cranial neural tumors
213. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide
214. Comparative effects of butyrate and N6, 2′-O-dibutyryladenosine-3′:5′-cyclic monophosphate on growth, differentiation and gene expression in U937 human monoblastoid cells
215. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity
216. Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuroblastoma cells by modulating nuclear import of p53
217. 15/17 Translocation, a consistent chromosomal change in acute promyelocytic leukaemia
218. Further evidence for a nonrandom chromosomal abnormality in acute promyelocytic leukemia
219. Retinoic acid in the treatment of acute promyelocytic leukemia: Inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events
220. In vitro radiosensitization of human cervical carcinoma cells by combined use of 13-cis-retinoic acid and interferon-alpha2a
221. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: A rationale for combination therapy with chemotherapeutic agents
222. The mechanism of retinoic acid radiosensitization is independent of AP-1 repression in a cervical carcinoma cell line
223. N-(4-hydroxyphenyl)retinamide: Interactions with retinoid-binding proteins/receptors
224. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
225. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation
226. Neuroblastoma
227. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study
228. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation
229. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma
230. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
231. Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee
232. Prognostic subgroups for undifferentiated neuroblastoma: Immunohistochemical study with anti-S-100 protein antibody
233. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an agelinked classification of neuroblastomas
234. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid
235. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro
236. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro
237. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines
238. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis
239. Complete maturation of neuroblastoma with bone metastases in documented stages
240. The molecular biology of acute promyelocytic leukemia
241. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer
242. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer
243. Retinoids in cancer therapy
244. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
245. Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia
246. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
247. Apoptosis of human leukemic HL-60 cells induced to differentiate by phorbol ester treatment
248. Clonal analysis of the response of HL-60 cells to retinoic acid and vitamin D in the presence or absence of leukocyte-conditioned medium
249. Schwannian cell differentiation of human neuroblastoma cell lines in vitro induced by bromodeoxyuridine
250. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression
251. Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RAR alpha fusion mRNA: A study in patients with acute promyelocytic leukemia following peripheral stem cell transplantation
252. Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80
253. Therapy of acute promyelocytic leukemia: All-trans retinoic acid and beyond
254. All-trans-retinoic acid in acute promyelocytic leukemia
255. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
256. Renal insufficiency after total body irradiation for pediatric bone marrow transplantation
257. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma
258. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia
259. Differential effects of staurosporine and retinoic acid on the vulnerability of the SH-SY5Y neuroblastoma cells: Involvement of bcl-2 and p53 proteins
260. Synergistic effect between doxorubicin and a low dose of all-trans-retinoic acid in MCF-7 breast cancer cell line
261. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients
262. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients
263. A mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line
264. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage
265. Differentiation of human neuroblastoma recapitulates neural crest development: Study of morphology, neurotransmitter enzymes, and extracellular matrix proteins
266. Induction of S 100 protein by 5-bromo-2′-deoxyuridine in human neuroblastoma cell lines
267. Retinoic acid induces insulin-like growth factor II expression in a neuroblastoma cell line
268. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation
269. Phase I trial of carboplatin, etoposide, melphalan, and local irradiation (CEM-LI) with purged autologous bone marrow transplantation (ABMT) for high risk neuroblastoma
270. Hypercalcemia: A dose-limiting toxicity associated with 13-cis-retinoic acid
271. All-trans-retinoic acid and pseudotumor cerebri
272. Differentiation of neuroblastoma cells induced by nerve growth factor in vitro
273. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications
274. Acute promyelocytic leukemia
275. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
276. Effects of interferon-alpha, beta, and gamma on the function of differentiated leukemic HL-60 cells induced by 1,25-dihydroxyvitamin D3
277. Differentiation therapy in acute myelogenous leukemia (non-APL)
278. Tiazofurin action in leukemia: Evidence for down-regulation of oncogenes and synergism with retinoic acid
279. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms
280. The effect of tamoxifen and fenretinimide on human colorectal cancer cell lines in vitro
281. p53 pathway in apoptosis induced by all-transretinoic acid in acute myeloblastic leukaemia cells
282. Alpha-tocopherol does not effect 13-cis-retinoic acid-mediated growth inhibition and N-myc down regulation in neuroblastoma cell lines
283. New agents for acute myelogenous leukemia